Arthritis, Rheumatoid Clinical Trial
Official title:
Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients
- The purpose of this study is to study the effectiveness of bazedoxifene in preventing
loss of bone mineral density (BMD) and trabecular bone score (TBS), and any fractures in
postmenopausal rheumatoid arthritis (RA) patients receiving long-term GCs.
- This is a randomized, controlled, open-label extension study for 48 or 56 weeks. At
study entry, all patients will receive elemental calcium (1200 mg daily) and vitamin D
(800 IU daily) and will be randomized by blocks of two to receive either bazedoxifene
(20 mg/day) or none.
- The purpose of this study is to study the effectiveness of bazedoxifene in preventing
loss of bone mineral density (BMD) and trabecular bone score (TBS), and any fractures in
postmenopausal rheumatoid arthritis (RA) patients receiving long-term GCs.
- This was a randomized, controlled, open-label study conducted for 56 weeks. Four trial
visits occurred over the course of the 56 weeks. At study entry, all patients who took
elemental calcium (1200 mg daily) and vitamin D (800 IU daily) were assigned by blocks
of two to receive either bazedoxifene (20 mg/day) (bazedoxifene group) or not (control
group).
- Randomization was performed by an independent coordinator. Participants were followed-up
at 24 weeks and 48 weeks with special attention to RA flares and occurrence of AEs.
- Demographic characteristics such as age, sex, and medications related to RA, as well as
laboratory result such as complete blood count (CBC), chemistry, and levels of
inflammatory markers were collected at enrollment. BMD and trabecular bone score (TBS)
were assessed at 0 and 48 weeks, and levels of bone turnover markers were assessed at 0,
24, and 48 weeks. At 56 weeks, the occurrence of AEs was assessed.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01682512 -
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
|
Phase 3 | |
| Completed |
NCT00539760 -
A Phase I Rheumatoid Arthritis Study in Healthy Volunteers
|
Phase 1 | |
| Active, not recruiting |
NCT03312465 -
Anatomical Shoulder Domelock System Study
|
||
| Completed |
NCT01208181 -
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
|
Phase 3 | |
| Completed |
NCT03254810 -
Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT01711814 -
A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
|
Phase 2 | |
| Completed |
NCT03315494 -
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers
|
Phase 1 | |
| Withdrawn |
NCT03241446 -
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
|
Phase 1 | |
| Completed |
NCT02553018 -
Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe
|
Phase 3 | |
| Completed |
NCT02748785 -
MTX Discontinuation and Vaccine Response
|
Phase 4 | |
| Active, not recruiting |
NCT02260778 -
Treat-to-target in RA: Collaboration To Improve adOption and adhereNce
|
N/A | |
| Completed |
NCT02569736 -
Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
|
||
| Completed |
NCT01750931 -
This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
|
Phase 2 | |
| Withdrawn |
NCT01204138 -
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA
|
Phase 2 | |
| Not yet recruiting |
NCT01154647 -
Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes
|
N/A | |
| Completed |
NCT00975130 -
Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
|
Phase 3 | |
| Completed |
NCT00913458 -
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
|
Phase 4 | |
| Completed |
NCT00973479 -
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
|
Phase 3 | |
| Completed |
NCT00660647 -
Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)
|
Phase 3 | |
| Completed |
NCT00550446 -
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
|
Phase 2 |